{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:26:15Z","timestamp":1784514375658,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T00:00:00Z","timestamp":1337731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The role of antitumour necrosis factor\u2010alpha (anti\u2010TNF) therapy for inflammatory bowel disease (IBD) among liver transplant recipients is largely unknown given the rarity of this population and the paucity of literature on the subject.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the safety and efficacy of anti\u2010TNF therapy for refractory IBD in the post liver transplant population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The liver transplant database at London Health Sciences Centre was searched to identify adult patients with <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> treated with anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy post transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six patients (five men, one woman) were identified, aged 28\u201365. All patients had cadaveric orthotopic liver transplants. Four patients required transplantation due to primary sclerosing cholangitis, one due to autoimmune hepatitis, and one due to biliary atresia. Five patients suffered from Crohn's disease and the remaining patient from indeterminate colitis. All patients were treated with infliximab 5\u00a0mg\/kg every 8\u00a0weeks after undergoing induction at weeks 0, 2 and 6, with the exception of one patient. The duration of infliximab therapy ranged from 8\u00a0weeks to 4\u00a0years. Four patients treated with infliximab experienced sustained improvement of their <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> symptoms post transplantation, as documented by Harvey\u2013Bradshaw Index scores demonstrating clinical remission. Of the remaining two patients, neither had sustained improvement of their <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> with infliximab or subsequent adalimumab. One patient was diagnosed with systemic lupus erythematosus and another with colorectal adenocarcinoma following anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy. Otherwise, no side effects were attributed to anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on this case series, anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy appears to be safe and effective for treating refractory <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> in patients post liver transplantation. These patients respond to anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy similar to those who have not been previously transplanted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05141.x","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T09:24:03Z","timestamp":1337765043000},"page":"159-165","source":"Crossref","is-referenced-by-count":45,"title":["The safety and efficacy of antitumour necrosis factor\u2010alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series"],"prefix":"10.1111","volume":"36","author":[{"given":"A.","family":"Sandhu","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Gastroenterology The University of Western Ontario and London Health Sciences Center  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Alameel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Alberta  Edmonton AL Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Dale","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Gastroenterology The University of Western Ontario and London Health Sciences Center  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Levstik","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Gastroenterology The University of Western Ontario and London Health Sciences Center  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chande","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Gastroenterology The University of Western Ontario and London Health Sciences Center  London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3280116ccc"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601219"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.3.325"},{"key":"e_1_2_6_9_1","first-page":"CD007216","article-title":"Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis","volume":"16","author":"Baumgart DC","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04873.x"},{"key":"e_1_2_6_11_1","first-page":"CD000297","article-title":"Cyclosporine for induction of remission in Crohn's disease","volume":"18","author":"McDonald JW","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_12_1","first-page":"CD004277","article-title":"Cyclosporine A for induction of remission in severe ulcerative colitis","volume":"1","author":"Shibolet O","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0210-5705(05)71523-5"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20263"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00695.x"},{"key":"e_1_2_6_16_1","first-page":"CD000478","article-title":"Azathioprine and 6\u2010mercaptopurine for maintenance of remission in ulcerative colitis","volume":"1","author":"Timmer A","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_17_1","first-page":"CD000545","article-title":"Azathioprine or 6\u2010mercaptopurine for inducing remission of Crohn's disease","volume":"2","author":"Sandborn W","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.035"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02280.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20037"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152769"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10758"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018804426724"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.11.5646-5653.2002"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031187"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.686"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066787"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21814"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21367"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00008"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.09.001"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90632-7"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep080"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.10.36"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22579"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.149419"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.5.639"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200512000-00018"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800820836"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01333.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.04.011"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01318204"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199802150-00017"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00624.x"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20528"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05141.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05141.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:56:21Z","timestamp":1698720981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05141.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,23]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05141.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05141.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,23]]}}}